A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

including five of AstraZeneca’s patents on its blockbuster inhaler Symbicort. The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

Seretide/Advair (fluticasone propionate + salmeterol; GlaxoSmithKline) and Symbicort (budesonide + formoterol fumarate dihydrate; AstraZeneca), which are ICS–LABA combinations, are other popular ...

AstraZeneca PLC (NASDAQ ... their respiratory drug Symbicort posted impressive 21% growth, complemented by Ultomiris’s 7% gain. The company is now making a significant push into the American ...